Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030667 · ClinicalTrials.gov registry record · Phase 2
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
A Phase 2 study of Recurrent Osteosarcoma and Recurrent Neuroblastoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT00030667: Completed Phase 2 study of Recurrent Osteosarcoma and Recurrent Neuroblastoma, sponsored by National Cancer Institute (NCI).
NCT00030667 is a Phase 2 study of Recurrent Osteosarcoma and Recurrent Neuroblastoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 100 participants, above the 59-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (69% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00030667, a Phase 2 study of Recurrent Osteosarcoma and Recurrent Neuroblastoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have relapsed or refractory solid tumors of childhood. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
Primary Outcome
95% confidence interval will be computed.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG imatinib mesylate
- OTHER pharmacological study
Study Locations (1)
California
- Children's Oncology Group - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2002-05 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
What the finished NCT00030667 record still lists
NCT00030667 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 59-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (69% higher).
The record links to 8 conditions, with Recurrent Osteosarcoma appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00030667 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00030667 about?
NCT00030667 is a clinical study titled "Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood". Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have relapsed or refractory solid tumors of childhood. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
What is the current status of trial NCT00030667?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2002-05. Estimated completion is 2005-12.
What conditions does trial NCT00030667 study?
This clinical trial studies the following conditions: Recurrent Osteosarcoma, Recurrent Neuroblastoma, Gastrointestinal Stromal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Soft Tissue Sarcoma.
What interventions are being tested in trial NCT00030667?
The interventions under investigation include: laboratory biomarker analysis (OTHER), imatinib mesylate (DRUG), pharmacological study (OTHER).
Who is sponsoring clinical trial NCT00030667?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00030667 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00030667's enrollment target sits among peer trials
100 3rd of 13 higher than 11 of 13 other Recurrent Osteosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Osteosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
RECRUITING · Phase 2
-
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
-
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia